

Nedosiran sodium

Cat. No.:	HY-132606A
CAS No.:	2247026-22-6
Molecular Weight:	22295.5
Target:	Lactate Dehydrogenase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

Nedosiran (sodium)

BIOLOGICAL ACTIVITY

Description

Nedosiran sodium is a GalNAc-dsRNA conjugate designed to inhibit production of the hepatic lactate dehydrogenase (LDH) enzyme.

REFERENCES

- [1]. Kevin Shee, et al. Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluria 1: A Compassionate Use Case Report. *Urology*. 2021 Oct;156:e147-e149.
- [2]. Gema Ariceta, et al. Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. *Kidney Int Rep*. 2021 Feb 3;6(4):1088-1098.
- [3]. Thomas A Forbes, et al. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria. *Br J Clin Pharmacol*. 2021 May 22.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA